Healthy adolescents and adults who had received 1 dose of a quadrivalent meningococcal conjugate vaccine 4 to 10 years previously will be randomized to receive either 1 dose of MenACYW conjugate vaccine or a licensed MCV4 . All participants will undergo immunogenicity assessment at baseline (pre-vaccination) and 1 month post-vaccination and will also be evaluated for safety up to Day 180 post-vaccination. In addition, a subset will have an additional blood sample collected at 6 days post-vaccination for immunogenicity assessment.